Bristol Myers Squibb Company $BMY Stock Holdings Increased by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 218.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,857 shares of the biopharmaceutical company’s stock after purchasing an additional 19,794 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,557,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in shares of Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the period. EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $32,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Bristol Myers Squibb during the third quarter valued at approximately $35,000. Finally, Garner Asset Management Corp acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $59.51 on Monday. The company’s 50 day moving average price is $58.46 and its 200 day moving average price is $55.92. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a market capitalization of $121.51 billion, a PE ratio of 16.71, a PEG ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the firm posted $1.80 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on BMY shares. HSBC boosted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Barclays started coverage on shares of Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. Piper Sandler restated an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Wells Fargo & Company restated an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $61.31.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.